AVANIR Pharmaceuticals to Present at UBS Warburg Global Life Sciences Conference.Business Editors/Health/Medical Writers BIOWIRE2K UBS Warburg Global Life Sciences Conference NEW YORK--(BUSINESS WIRE)--Sept. 24, 2003 AVANIR Pharmaceuticals (AMEX AMEX See: American Stock Exchange : AVN) announced that it is participating in the UBS Warburg Global Life Sciences Conference taking place September 22 - 25, 2003, at The Plaza Hotel in New York. In his presentation, scheduled for 12:00 p.m., September 24, 2003, President and Chief Executive Officer Dr. Gerald J. Yakatan will focus on AVANIR's drug candidates in clinical development. AVANIR's lead product, Neurodex(TM), is a late stage, first-in-class drug candidate for central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency that targets two distinct patient populations. Neurodex is in Phase III clinical development for the treatment of pseudobulbar affect in neurodegenerative diseases, including Alzheimer's, multiple sclerosis, Lou Gehrig's disease Lou Geh·rig's disease n. See amyotrophic lateral sclerosis. or ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. , Parkinson's, traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain and stroke. AVANIR is currently enrolling multiple sclerosis patients in a final Phase III study and anticipates submitting an NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any in 2004. In June 2003, AVANIR completed a successful Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II studying Neurodex in patients with diabetic neuropathic pain. AVANIR's allergy and asthma drug candidate, AVP AVP arginine vasopressin. 13358, is in a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I . AVP 13358 is an orally active compound designed to counteract the body's response to allergens by selectively inhibiting the production of the critical mediator (IgE) and a group of Th2 cytokines (Il-4, Il-5, Il-13) that play key roles in the pathogenesis of allergy and asthma. AVANIR Pharmaceuticals is a drug discovery and development company focused on the development of treatments for central nervous system disorders and inflammatory diseases. The company's first commercialized FDA-approved product, Abreva(R), is marketed in North America by GlaxoSmithKline and is the leading over-the-counter product for the treatment of cold sores. The company's lead product candidate, Neurodex(TM), is in Phase III clinical development for pseudobulbar affect and in Phase II clinical development for neuropathic pain. An internally developed small molecule, AVP 13358, is in a Phase I clinical trial for the treatment of allergy and asthma. Using its proprietary Xenerex(TM) technology, AVANIR also develops human monoclonal antibodies for infectious diseases and other therapeutic applications. Further information about AVANIR can be found at www.avanir.com. The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion